Form 4: PTC Therapeutics Officer Receives Equity Grants

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, was granted 18,020 restricted stock units and options to purchase 43,750 shares of common stock.

Summary

• Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, Inc. (PTCT), received equity grants on January 2, 2026.
• The grants include 17,500 restricted stock units (RSUs) directly and 520 RSUs indirectly (by spouse), totaling 18,020 RSUs. These RSUs vest in four equal annual installments starting January 2, 2027.
• Additionally, Almstead was granted options to purchase 43,750 shares of common stock with an exercise price of $76.74. These options vest over four years, with 25% vesting on January 2, 2027, and 6.25% quarterly thereafter, beginning April 2, 2027, and expire on January 1, 2036.
• Following these transactions, Almstead directly beneficially owns 118,382 shares of common stock and 43,750 derivative securities (stock options). His spouse indirectly beneficially owns 6,956 shares of common stock.
• The reported common stock holdings include 257 shares acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.

Sentiment

Score: 6

Explanation: The filing reports routine executive equity compensation grants, which are generally neutral to slightly positive as they align management interests with shareholder value, without indicating any extraordinary events or financial performance.

Positives

• Grant of 18,020 restricted stock units (RSUs) to the Chief Technical Operations Officer, aligning executive interests with long-term shareholder value.
• Grant of options to purchase 43,750 shares of common stock, further incentivizing performance and retention.
• Inclusion of 257 shares acquired through the employee stock purchase plan, indicating employee participation in company ownership.

Future Outlook

The filing details vesting schedules for the granted restricted stock units and stock options, indicating future share issuances upon meeting vesting conditions over the next four years.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the form of equity grants, a common practice across industries, including biotechnology, to align management incentives with long-term company performance and shareholder value.

Related Party Transactions

• The grants of restricted stock units and stock options to Neil Gregory Almstead, an officer of PTC Therapeutics, Inc., constitute related party transactions as part of his executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholders, potentially encouraging long-term value creation. Future share issuance upon vesting/exercise will result in minor dilution, which is typical for executive compensation plans.
• Employees: The inclusion of shares acquired through the employee stock purchase plan indicates broader employee participation in company ownership, fostering a sense of shared success.

Next Steps

• Vesting of restricted stock units in four equal annual installments, commencing January 2, 2027.
• Vesting of stock options over four years, with 25% on January 2, 2027, and 6.25% quarterly thereafter, beginning April 2, 2027.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation